Mucinous colorectal adenocarcinoma: clinical pathology and treatment progress

doi:10.3877/cma.j.issn.2095-3224.2022.04.009

Abstract

Abstract:

Mucinous colorectal adenocarcinoma is a distinct subtype of colorectal adenocarcinoma with characteristic histopathologic features, exhibiting unique patterns of tumor growth, metastasis, and recurrence. Mucinous adenocarcinoma is insensitive to the current adenocarcinoma-based treatment strategy and with poor prognosis. The rapid of development of concepts with individualized treatment have led clinicians to focus on mucinous subtypes. In this review, we discuss the histopathology of mucinous colorectal adenocarcinoma and provide an update on its prognosis and therapeutics from recent literature.

Key words: Colorectal neoplasms, Mucinous carcinoma, Treatment progress

Chaolin Deng, Bin. Wu. Mucinous colorectal adenocarcinoma: clinical pathology and treatment progress[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2022, 11(04): 325-328.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2022.04.009

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2022/V11/I04/325

References 28

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2]	Verhulst J, Ferdinande L, Demetter P, et al. Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta-analysis[J]. J Clin Pathol, 2012, 65(5): 381-388.
[3]	Hugen N, van Beek JJ, de Wilt JH, et al. Insight into mucinous colorectal carcinoma: clues from etiology[J]. Ann Surg Oncol, 2014, 21(9): 2963-2970.
[4]	Walsh MD, Clendenning M, Williamson E, et al. Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype[J]. Mod Pathol, 2013, 26(12): 1642-1656.
[5]	Hugen N, Simons M, Halilovic A, et al. The molecular background of mucinous carcinoma beyond MUC2[J]. J Pathol Clin Res, 2015, 1(1): 3-17.
[6]	Sicard JF, Le Bihan G, Vogeleer P, et al. Interactions of intestinal bacteria with components of the intestinal mucus[J]. Front Cell Infect Microbiol, 2017, 7: 387.
[7]	Li S, Peppelenbosch MP, Smits R. Bacterial biofilms as a potential contributor to mucinous colorectal cancer formation[J]. Biochim Biophys Acta Rev Cancer, 2019, 1872(1): 74-79.
[8]	Numata M, Shiozawa M, Watanabe T, et al. The clinicopathological features of colorectal mucinous adenocarcinoma and a therapeutic strategy for the disease[J]. World J Surg Oncol, 2012, 10: 109.
[9]	Hugen N, Brown G, Glynne-Jones R, et al. Advances in the care of patients with mucinous colorectal cancer[J]. Nat Rev Clin Oncol, 2016, 13(6): 361-369.
[10]	McCawley N, Clancy C, O'Neill BD, et al. Mucinous rectal adenocarcinoma is associated with a poor response to neoadjuvant chemoradiotherapy: A systematic review and meta-analysis[J]. Dis Colon Rectum, 2016, 59(12): 1200-1208.
[11]	Xiao S, Huang J, Zhang Y, et al. Endoscopy biopsy is not efficiency enough for diagnosis of mucinous colorectal adenocarcinoma[J]. Discov Oncol, 2021, 12(1): 44.
[12]	Li ZH, You DY, Gao DP, et al. Role of CT scan in differentiating the type of colorectal cancer[J]. Onco Targets Ther, 2017, 10: 2297-2303.
[13]	Yu MH, Kim YJ, Park HS, et al. Imaging patterns of intratumoral calcification in the abdominopelvic cavity[J]. Korean J Radiol, 2017, 18(2): 323-335.
[14]	Argiles G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2020, 31(10): 1291-1305.
[15]	Hosseini S, Nguyen N, Mohammadianpanah M, et al. Predictive significance of mucinous histology on pathologic complete response rate following capecitabine-based neoadjuvant chemoradiation in rectal cancer: a comparative study[J]. J Gastrointest Cancer, 2019, 50(4): 716-722.
[16]	Reggiani Bonetti L, Lionti S, Domati F, et al. Do pathological variables have prognostic significance in rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and surgery?[J]. World J Gastroenterol, 2017, 23(8): 1412-1423.
[17]	Reynolds IS, Furney SJ, Kay EW, et al. Meta-analysis of the molecular associations of mucinous colorectal cancer[J]. Br J Surg, 2019, 106(6): 682-691.
[18]	Luo C, Cen S, Ding G, et al. Mucinous colorectal adenocarcinoma: clinical pathology and treatment options[J]. Cancer Commun (Lond), 2019, 39(1): 13.
[19]	Reynolds IS, O'Connell E, Fichtner M, et al. Mucinous adenocarcinoma is a pharmacogenomically distinct subtype of colorectal cancer[J]. Pharmacogenomics J, 2020, 20(3): 524-532.
[20]	Stylianopoulos T, Jain RK. Combining two strategies to improve perfusion and drug delivery in solid tumors[J]. Proc Natl Acad Sci USA, 2013, 110(46): 18632-18637.
[21]	O'Connell E, Reynolds IS, McNamara DA, et al. Resistance to cell death in mucinous colorectal cancer-a review[J]. Cancers (Basel), 2021, 13(6): 1389.
[22]	Foxtrot Collaborative G. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial[J]. Lancet Oncol, 2012, 13(11): 1152-1160.
[23]	Weitz JI, Bauersachs R, Becker B, et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial[J]. JAMA, 2020, 323(2): 130-139.
[24]	Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers[J]. Nat Med, 2020, 26(4): 566-576.
[25]	Llosa NJ, Luber B, Siegel N, et al. Immunopathologic stratification of colorectal cancer for checkpoint blockade immunotherapy[J]. Cancer Immunol Res, 2019, 7(10): 1574-1579.
[26]	Benson AB, Venook AP, Al-Hawary MM, et al. NCCN guidelines insights: colon cancer, version 2.2018[J]. J Natl Compr Canc Netw, 2018, 16(4): 359-369.
[27]	Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015, 372(26): 2509-2520.
[28]	Corcoran RB, Atreya CE, Falchook GS, et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-Mutant colorectal cancer[J]. J Clin Oncol, 2015, 33(34): 4023-4031.

Please choose a citation manager

Content to export